The First Cholesterol Pill of Its Kind Can Cut LDL by Nearly 60%. Here Is What It Cannot Prove Yet

The FDA has approved Lipfendra, the first oral PCSK9 inhibitor, after two placebo-controlled trials involving 3,207 adults showed average LDL reductions of 56% and 59%. The daily pill could widen access to a powerful treatment class previously limited to injections, although it has not yet proved that it prevents heart attacks or strokes.